Exchange: NASDAQ·Updated 09:04 PM EDT

VKTX News

News
all
press releases
Viking Therapeutics' Oral Obesity Drug Advances to Phase 3 Testing. Is Now the Time to Buy This Biotech Stock?
Key PointsViking Therapeutics will soon enter phase 3 trials with its weight loss pill candidate...
Nasdaq News: Markets
Viking Therapeutics' Oral Obesity Drug Advances to Phase 3 Testing. Is Now the Time to Buy This Biotech Stock?
Key PointsViking Therapeutics will soon enter phase 3 trials with its weight loss pill candidate...
Nasdaq News: Markets
More News
Viking Therapeutics, Inc. (VKTX) Exceeds Market Returns: Some Facts to Consider
The latest trading day saw Viking Therapeutics, Inc. (VKTX) settling at $28.53, representing a +2.88% change from its previous close.
Zacks
Viking Therapeutics, Inc. (VKTX) Dips More Than Broader Market: What You Should Know
In the closing of the recent trading day, Viking Therapeutics, Inc. (VKTX) stood at $27.73, denoting a -2.84% move from the preceding trading day.
Zacks
LLY Stock Down 2% in 3 Months: Is the Dip a Buying Opportunity?
LLY's recent dip reflects valuation and competition concerns, but strong GLP-1 demand, pipeline growth and diversification support its long-term outlook.
Zacks
VKTX Advances Obesity Program With New Oral Maintenance Study
VK2735's oral maintenance study could expand Viking Therapeutics' obesity strategy by helping sustain weight loss with less frequent dosing.
Zacks
INSM Stock Slides on CFO Exit, Reiterates '26 Sales View
Insmed shares slide after CFO Sara Bonstein's surprise exit, though the company reaffirms 2026 revenue guidance for Brinsupri and Arikayce.
Zacks
VKTX Down 16% in a Month: Time to Invest or Exit the Stock?
Viking Therapeutics faces dilution and rising obesity competition, but VK2735's pipeline progress could offer catalysts and support a rebound.
Zacks
Viking Therapeutics Announces Initiation of VK2735 Oral Maintenance Dosing Clinical Trial in Patients with Obesity
Viking Therapeutics Announces Initiation of VK2735 Oral Maintenance Dosing Clinical Trial in Patients with Obesity Viking Therapeutics Announces Initiation of VK2735 Oral Maintenance Dosing Clinical Trial in Patients with ObesityPR NewswireSAN DIEGO, Oct. 6, 2026Study to Explore Oral Maintenance...
PR Newswire
LLY Highlights New Efficacy Data From Foundayo and EloraTZP Studies
Eli Lilly's new data show Foundayo's cardiovascular safety and metabolic benefits, while EloraTZP delivers greater weight loss and A1C reduction in a mid-stage study.
Zacks
Viking Therapeutics, Inc. (VKTX) Stock Declines While Market Improves: Some Information for Investors
Viking Therapeutics, Inc. (VKTX) closed the most recent trading day at $30.51, moving 6.41% from the previous trading session.
Zacks

Advertisement|Remove ads.